Literature DB >> 17174090

Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.

Thuy Tran1, Clifford Quan, Conrad Yap Edosada, Mark Mayeda, Christian Wiesmann, Dan Sutherlin, Beni B Wolf.   

Abstract

The structure-activity relationship of various N-acyl-Gly-, N-acyl-Sar-, and N-blocked-boroPro derivatives against three prolyl peptidases was explored. Several N-acyl-Gly- and N-blocked-boroPro compounds showed low nanomolar inhibitory activity against fibroblast activation protein (FAP) and prolyl oligopeptidase (POP) and selectivity against dipeptidyl peptidase-4 (DPP4). N-Acyl-Sar-boroPro analogs retained selectivity against DPP4 and potent POP inhibitory activity but displayed decreased FAP inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174090     DOI: 10.1016/j.bmcl.2006.11.072

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Authors:  Koen Jansen; Leen Heirbaut; Jonathan D Cheng; Jurgen Joossens; Oxana Ryabtsova; Paul Cos; Louis Maes; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2013-03-18       Impact factor: 4.345

2.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

3.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Sarah E Poplawski; Jack H Lai; Youhua Li; Zhiping Jin; Yuxin Liu; Wengen Wu; Yong Wu; Yuhong Zhou; James L Sudmeier; David G Sanford; William W Bachovchin
Journal:  J Med Chem       Date:  2013-04-29       Impact factor: 7.446

4.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

5.  Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging.

Authors:  Romana Meletta; Adrienne Müller Herde; Aristeidis Chiotellis; Malsor Isa; Zoran Rancic; Nicole Borel; Simon M Ametamey; Stefanie D Krämer; Roger Schibli
Journal:  Molecules       Date:  2015-01-27       Impact factor: 4.411

6.  Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging.

Authors:  Diana Trujillo-Benítez; Myrna Luna-Gutiérrez; Guillermina Ferro-Flores; Blanca Ocampo-García; Clara Santos-Cuevas; Gerardo Bravo-Villegas; Enrique Morales-Ávila; Pedro Cruz-Nova; Lorenza Díaz-Nieto; Janice García-Quiroz; Erika Azorín-Vega; Antonio Rosato; Laura Meléndez-Alafort
Journal:  Molecules       Date:  2022-01-01       Impact factor: 4.411

7.  A solid-phase approach for the synthesis of α-aminoboronic acid peptides.

Authors:  Blake E Daniels; Craig E Stivala
Journal:  RSC Adv       Date:  2018-01-16       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.